Last reviewed · How we verify
Lansoprazole/Amoxicillin/Clarithromycin
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid while simultaneously disrupting bacterial cell wall and protein synthesis.
This triple-therapy combination eradicates Helicobacter pylori by suppressing gastric acid while simultaneously disrupting bacterial cell wall and protein synthesis. Used for Helicobacter pylori eradication in patients with peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | Lansoprazole/Amoxicillin/Clarithromycin |
|---|---|
| Also known as | Lansoprazole triple therapy (LAC) |
| Sponsor | HK inno.N Corporation |
| Drug class | Proton pump inhibitor + antibiotic combination |
| Target | H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion, creating an environment hostile to H. pylori. Amoxicillin and clarithromycin are antibiotics that work synergistically—amoxicillin disrupts bacterial cell wall synthesis while clarithromycin inhibits bacterial protein synthesis. Together, these three agents achieve high eradication rates of H. pylori infection.
Approved indications
- Helicobacter pylori eradication in patients with peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Taste disturbance
- Vomiting
Key clinical trials
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile (NA)
- The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection (PHASE3)
- Helicobacter Pylori Eradication Study (PHASE4)
- Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin (PHASE2)
- Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication (PHASE3)
- Vonoprazan-Based Triple Therapy in Comparison With Extended Sequential Therapy (PHASE4)
- Exploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: